Early mortality (EM; death 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. 
| I N T R O D U C T I O N
Even as the new era of multiple myeloma (MM) treatment has gone beyond novel agents to include aggressive incorporation of stem cell transplant and monoclonal antibodies, early mortality (EM) remains a major clinical issue that physicians need to be able to recognize the risk for and to prevent among their patients with newly diagnosed MM (NDMM). EM in NDMM is often described within the literature as death that occurs 2 to 12 months after diagnosis.
1,2 Among patients with NDMM, EM can be influenced by patient age, comorbidities, PS, therapy, and disease biology. [1] [2] [3] [4] [5] [6] Risk factors of EM in patients with MM have been investigated in several studies, including a study that used data from the IFM 2005-01 phase 3 trial to develop a prognostic index of EM. 7 That study constructed a prognostic index of early MM progression-related death within 2 years of treatment initiation based on 3 independent prognostic variables: lactate dehydrogenase levels higher than normal, International Staging System (ISS) stage III, and adverse cytogenetics (t [4;14] and/or del[17p]). 7 However, that index did not allow for differential weighting of each of the 3 prognostic variables, and its applicability is limited to transplant-eligible patients (who comprise approximately 40% of patients with NDMM) who would meet the strict eligibility criteria of clinical trials in MM. By contrast, prediction matrix models similar to those created for cardiovascular disease and rheumatoid arthritis 8, 9 can be used to calculate the risk of specific outcomes, such as mortality, and allow for differential weighting for the various modelspecific risk factors. Identifying patients with an increased risk of EM is critical for physicians to consider implementing different therapeutic
approaches. Prediction tools that analyze both biological and clinical features have also been successfully used in several hematologic malignancies to predict EM. In acute myeloid leukemia, age, performance status (PS), and intensity of treatment have motivated the development of novel treatment paradigms. 10 In diffuse large B-cell lymphoma, molecular classification and positron emission tomography scans have introduced earlier decisions in the clinical treatment course to improve outcomes. 11, 12 Much of what is currently known about risk factors for EM in patients with NDMM is based on data from clinical trial populations, which often differ from unselected patient populations due to exclusion of patients who are older, have comorbidities, are in poorer health, or are often ineligible for stem cell transplant. An observational registry offers the unique opportunity to report a broad set of baseline characteristics and treatment outcomes while assessing associations between NDMM biology, patient characteristics, comorbidities, and treatment selection with outcomes and overall survival. Thus, the Connect MM Registry investigators sought to review the registry patient population to get a comprehensive look at the incidence and factors associated with EM. The registry included patients independent of selection bias, age, therapy, PS, and comorbidities, which allowed for a cross-sectional evaluation of patients with NDMM. Using data from a largely unselected patient population reflective of the heterogeneous patients seen in routine clinical practice, the registry investigators were able to develop a prognostic tool to assess the risk of EM that allows for differential weighting of risk factors. Here, we describe the construction of an early mortality prediction matrix (EMPM) in a population that includes both elderly and non-transplant-eligible patients.
| M E T H O D S
The Connect MM REGISTRY is a US-based, multicenter, prospective, 17 were generated for significant variables with 70% nonmissing data. The final model parameters were estimated for each imputed data set, and the results, across the imputed data sets, were combined using the Rubin method.
Construction of prediction matrices was based on a logistic model for mortality 180 days after enrollment. Internal cross-validation of the model was performed with bootstrap resampling (100 samples) from the empirical data, using the Harrell C-index 18 to determine the concordance probability. For the logistic model, the concordance probability is identical to the area under the receiver operating characteristic curve for the model. A prediction matrix is a summary of an estimated logistic regression that illustrates the predicted probability of the modeled outcome at constituent levels of each of the predictors. In this way, the prediction matrix offers insight into the relative importance of each covariate and can be used to highlight the differential impact of predictors at different constituent levels.
External validation of the logistic model was also performed using data from the phase 3 MM-015 trial, which investigated the safety and efficacy of lenalidomide in combination with melphalan, and prednisone in patients aged 65 years with NDMM. 19 The EQ-5D mobility score, which was not collected in the MM-015 study, was estimated using Karnofsky PS (Karnofsky PS scores of 50 were mapped to the "confined to bed" mobility item, scores between 60 and 80 were mapped to "some problem walking about," and scores of 90 were mapped to "no problem in walking about"). were conducted using the rms package of the R statistical programming language using the methods of Harrell. 
| Baseline characteristics
At baseline, patients with EM were older than patients who survived 
| Treatment
The majority of patients in both groups (approximately 81%) were enrolled within community practices, and approximately 18% were enrolled in academic centers ( 
| Causes of death
For the 102 patients with EM, 39.2% (2.7% of the total enrolled patients) of deaths were related to MM progression and 32.4% were related to nonmyeloma causes. Common causes of death in patients with EM included heart failure, pneumonia, other infection, and renal failure, and 28.4% were listed as other or unknown causes (Table 2) .
For the 1391 patients surviving for > 180 days, 31.5% died within the time frame of this analysis. The majority of these deaths (58.2%) were directly attributed to myeloma progression and 5% were due to nonmyeloma causes. Common causes of death included renal failure, heart failure, pneumonia, and other infections; in 25.8% of patients, the cause of death was listed as other or unknown.
| Logistic regression analysis
In the univariate analysis, 15 baseline factors were statistically associated with EM (Table 3 ). The 15 factors were included in the multivariate logistic regression analysis and following an iterative variable selection process, 6 variables were identified as significantly associated with a higher likelihood of EM: age (> 75 years), prior hypertension, higher ECOG PS, higher ISS stage, lower platelet count, and lower EQ-5D mobility score (Table 3) . Additionally, a trend toward increased likelihood of EM was associated with renal insufficiency (serum creatinine > 2 mg/dL), making renal insufficiency a seventh factor. The 7 factors identified in the multivariate regression analysis were used to construct a prediction matrix that estimated the probability of EM ( Figure 1A ).
| Validation
Internal cross-validation of this model found a 2.2% reduction in the concordance probability in the test bootstrap resampling estimate compared with the training bootstrap estimate. The training optimismadjusted concordance probability of the fitted logistic model was estimated as 74.3% (95% CI: 68.7%-80.0%); a concordance probability significantly greater than 50% is indicative of a good predictive model.
Consistent with these results, external validation using data from patients with NDMM enrolled in the MM-015 phase 3 trial resulted in a concordance probability of 76.7% for the logistic model ( Figure 1B) .
A second external validation was conducted using data from patients with NDMM enrolled in the phase 3 FIRST trial, which demonstrated a concordance probability of 71.8% for the logistic model ( Figure 1C ).
Validation using data from the 1492 Cohort 2 patients who had 10 months of follow-up resulted in a concordance probability of 71.4% for the logistic model ( Figure 1D ). Patient characteristics were similar between Cohort 1 and Cohort 2: median age was 67 years for both cohorts; 57% and 58% were male, respectively; 28% and 27%
had ISS stage III disease, respectively. A full report on the second cohort of patients (n 5 1518) enrolled from December 2012 to April 2016 into the Connect MM REGISTRY will be provided at a later date.
| DISCUSSION
Before the era of novel agents, the incidence of EM was 10% to 14%
in patients with NDMM. 1, 5, 15, 23 Advances in myeloma treatment (i.e., therapeutic approaches and supportive care) have improved longterm outcomes and survival. However, despite increasing awareness of its phenomenon, EM remains an area of unmet medical need and not all patients benefit from the long-term impact of novel agents. EM was further brought to light by the impassioned management issues with newly diagnosed patients by Gonsalves et al. 24 The authors defined the incidence of EM from phase 3 trials and outlined key management strategies for patients with NDMM to help mitigate EM, while also touching on the patients most at risk for EM. The EMPM described here offers clinicians the parameters to identify and treat patients with NDMM at risk for EM and the opportunity to address EM in clinical trials.
The prognosis of NDMM depends on staging, patient features, disease biology, and treatment outcomes. 3 Current tools designed for risk stratification use the revised ISS (r-ISS) for MM from the International Myeloma Working Group (IMWG); the r-ISS is important for long-term prognosis but has not been used to identify patients at risk for EM. 25 Because the r-ISS is a point-based system, it is less possible to assess the relative contribution of each element. In addition, the r-ISS is predominantly based on disease-specific risk factors and does not account for patient-specific risk factors. Similar to the r-ISS, the frailty score is a point-based system that combines age, functional status, and comorbidities to predict long-term survival and feasibility of a treatment regimen in elderly patients with NDMM. 26 Combining the frailty score with the r-ISS stage improves the prognostic value of each score individually to predict long-term survival, but neither score combined or alone has been used to identify patients at the highest risk for EM.
Prognostic studies have provided physicians with a better understanding of the relationship between aggressiveness of disease and survival in patients with NDMM. However, significant gaps remain in our understanding of the best methods of stratifying risk in these patients, incorporating patient-and disease-specific risk factors and the relative contributions of individual risk factors. The existing pointbased systems make it difficult to accurately predict outcomes in patients who have a mixture of high-and standard-risk characteristics.
14, [25] [26] [27] Furthermore, the point-based models are primarily based on data from interventional clinical trials and may not represent the general MM patient population. Therefore, using data from a patient registry, we set out to create an EMPM model that allows differential weighting of the impact of individual patient-and disease-specific risk factors.
Patient comorbidities have been associated with higher mortality in various clinical trials of patients with MM. 4, 16, [28] [29] [30] [31] [32] [33] [34] For some patients with MM, comorbidities are a direct cause of death, but they also put patients at risk for early disease-related mortality by compromising the ability to effectively give treatment. 4, 28, 30, 31 Although the 6.8% incidence of EM observed in this study suggests the benefit of novel agents and improved supportive care, there are several issues to be noted.
Patients in our study with EM were older and in generally poorer health, with higher rates of comorbidities (including diabetes and hypertension), greater burden of disease, and high-risk features such as ISS stage III and the presence of del(17p) cytogenetics. Consistent with these a Proportion due to deaths not directly attributed to myeloma progression. b Other deaths included sepsis (n 5 7), cardiac related (n 5 3), lung and brain cancer (n 5 2), and single occurrences of death due to aspiration pneumonitis, complications from anasarca, emphysema, gastrointestinal hemorrhage, liver failure, multiorgan system failure, perforated diverticulum, and respiratory arrest.
observations, the median time from diagnosis to enrollment was 25 days, indicating that this study did not likely select for a healthy population of patients with MM. In our prediction matrix, lower mobility score, age > 75 years, history of hypertension, lower platelet count, higher ECOG PS, high ISS disease stage, and renal insufficiency were associated with a higher likelihood of EM. Although identified as FIG URE 1 EMPM with estimated probability of mortality within 180 days (A) and external validation model using data from previous trials (B, C, and D). (A) Green, yellow, and red shading represent lower, intermediate, and higher probabilities of EM, respectively. As an example in the practical use of the EMPM, consider a patient with NDMM enrolled in the Connect MM Registry. This patient answered "I have some problems walking about" to the EQ-5D mobility question, and his platelet count was 150 3 10 9 /L. This patient had an ECOG PS of 2, had a history of hypertension, and was 56 years old. He had ISS stage III disease and a serum creatinine level of 3.19 mg/dL. Entering these baseline factors into the EMPM showed that this patient had a 57% chance of mortality within the first 180 days on study and, in actuality, the patient died at 26 days. Creat indicates serum creatinine and PC, platelet count. (B) Data from MM-015, (C) data from the FIRST trial, and (D) data from the second cohort of the Connect MM registry. Triangles represent observations in groups of 30 (groups ordered from most probable to least probable) for whom the actual probabilities (from the MM-015, FIRST trial, or Cohort 2 data) are plotted against the predicted probabilities (based on the Connect MM logistic model). The solid line and the curved dotted line (nonparametric curve) are the fitted curves for the plot of actual and predicted probabilities. The C-index or concordance probability is the probability that a randomly selected pair of patients in the independent external data set, one with a poorer survival outcome than the other, will be correctly differentially identified based on inputting the 2 patients' baseline prognostic characteristics in the fitted model obtained from the Connect MM Registry.
significant in the univariate analysis, albumin level, b 2 -microglobulin level, degree of anemia, history of diabetes, hypercalcemia, IMWG risk, del(17p) mutation, and self-care score from EQ-5D were not found to be independently associated with EM in the multivariate analysis. In addition, patients with EM required more radiation, which likely limited their ability to receive more aggressive therapy ( 2 novel therapies or triplet therapy) or potentially led to a delay in initiating systemic therapy. It is important to note that although a lower proportion of patients with EM were treated with 2 novel therapies, this was not a significant factor for EM in the multivariate analysis. Lastly, the current HRQOL indicates health-related quality of life; LLN, lower limit of normal; MGUS, monoclonal gammopathy of undetermined significance; and VTE, venous thromboembolism. a Baseline characteristics with P values in bold were considered significant at P < .15 in the univariate analysis. b Albumin and b 2 -microglobulin levels were analyzed as independent variables separate from ISS stage to understand their individual impact in the final model. c Baseline characteristics for which multivariate data are not presented are those that were screened out because either they had univariate P > .15 or they were not significant in the variable selection step.
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analysis of patients with high-risk disease was limited by too few patients with conventional cytogenetic and FISH data. 13 However, as the data mature, a future analysis can be conducted to characterize patients with high-risk disease who did not die within 180 days compared with patients with non-high-risk disease who had a longer survival time.
The There are several inherent limitations to using data from patient registries. Because data collection is more passive than collection of interventional trial data, there is an increased likelihood of missing data. 35 If a patient is new to a clinic, complete medical and clinical history may not be available. Furthermore, data is as reported by the treating physician and it is often difficult to interpret missing data. 36 To reduce data missingness and inaccuracies, we conducted comprehensive data review, including issuing queries to sites and conducting limited site monitoring. Registry patients are also treated in community practices where delivery and choice of care is at physician discretion. Finally, although generalizability of registry data to a disease population as a whole is considered a strength, it is dependent on the source population from which the registry enrolls patients. 37 In conclusion, high-quality systematic research to identify patients at risk for EM have been limited. The EMPM is the first weight-based model that accounts for both patient-and diseasespecific risk factors. Importantly, our study highlighted common This model also supports additional studies in these subsets of patients to evaluate potential strategies to reduce the risk of EM.
Other strengths of the EMPM are ease of use and the ability to rapidly implement into routine clinical practice and consider risk-adapted approaches to disease management.
